title: Glucose, insulin and potassium for heart protection during cardiac surgery.
abstract: BACKGROUND
  Coronary artery bypass grafting with hypothermic cardiac arrest and cardiopulmonary bypass (CPB) is associated with myocardial injury. Our study investigated whether an infusion of glucose, insulin and potassium (GIK) during elective coronary artery bypass surgery decreases myocardial cell death.
  
  
  METHODS
  We measured cardiac troponin I (cTnI), a myofibrillar structural protein, which is a sensitive and specific indicator of myocytic injury. With ethics committee approval, 42 patients were enrolled into a randomized, prospective, double-blinded study. In the GIK group, 500 ml of 50% dextrose solution containing 100 IU insulin and potassium 80 mmol was infused at the rate of 0.75 ml kg(-1) h(-1). Patients in the non-GIK group received 5% dextrose solution at the same rate. Arterial blood samples were taken before induction of anaesthesia, after removal of the aortic clamp and 6 and 12 h after CPB.
  
  
  RESULTS
  In both groups there was an increase in cTnI concentration (P<0.05), which was greatest about 6 h after CPB. At no time did the cTnI concentration differ between the two groups.
  
  
  CONCLUSIONS
  The results suggest that GIK does not decrease the irreversible myocardial damage associated with routine coronary artery bypass surgery.
authors.affiliation: Department of Anaesthesia, Kings College Hospital, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Bruemmer-Smith
authors.forename: M S
authors.initials: MS
authors.lastname: Avidan
authors.forename: B
authors.initials: B
authors.lastname: Harris
authors.forename: S
authors.initials: S
authors.lastname: Sudan
authors.forename: R
authors.initials: R
authors.lastname: Sherwood
authors.forename: J B
authors.initials: JB
authors.lastname: Desai
authors.forename: F
authors.initials: F
authors.lastname: Sutherland
authors.forename: J
authors.initials: J
authors.lastname: Ponte
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002314:Cardioplegic Solutions / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D005947:Glucose / Q000627:therapeutic use*; D006801:Humans; D007036:Hypothermia, Induced; D007328:Insulin / Q000627:therapeutic use*; D007430:Intraoperative Care / Q000379:methods*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control*; D011188:Potassium / Q000627:therapeutic use*; D011446:Prospective Studies; D019210:Troponin I / Q000097:blood
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D002314:Cardioplegic Solutions; D007328:Insulin; D019210:Troponin I; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium